David Walker, ACR 2020 – Filgotinib for the Treatment of Rheumatoid Arthritis
We talked to David Walker (Northumbria Healthcare NHS Trust, Newcastle upon Tyne, UK) about filgotinib for the relief of pain, fatigue and improved quality of life in patients with rheumatoid arthritis (Clinical Trial Identifier: NCT02873936). The abstract ‘Filgotinib Provided Rapid and Sustained Relief of Pain and Fatigue and Improved Health-Related Quality of Life in Patients with Rheumatoid Arthritis and Inadequate Response to Biologic DMARDs’ (ABSTRACT NUMBER:1215) was presented at the virtual ACR Convergence 2020, 5-9 November 2020.
Questions
- What is filgotinib? (0:06)
- How do outcome measures recommended by regulators differ from those considered important by patients? (0:24)
- What did the FINCH-2 study show? (2:12)
- What is the importance of using patient reported outcomes in clinical trials? (3:21)
Disclosures: Speaker meetings and advisory boards for: Lilly, Gilead, Abbvie, Pfizer and Janssen.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the ACR 2020 Annual Meeting (Virtual).
